½ÃÀ庸°í¼­
»óǰÄÚµå
1800749

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå : Á¦Ç° À¯Çü¡¤ÀûÀÀÁõ À¯Çü¡¤ÃÖÁ¾»ç¿ëÀÚ¡¤±¹°¡º° ºÐ¼®¡¤¿¹Ãø(2025-2035ÇØ)

Asia-Pacific Next-Generation Intervention Cardiology Market: Focus on Product Type, Indication Type, End User, and Country - Analysis and Forecast, 2025-2035

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BIS Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå ±Ô¸ð´Â 2024³â 5¾ï 3,409¸¸ ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ µ¿¾È 8.46%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2035³â¿¡´Â 13¾ï 5,370¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÇ·á´Â Â÷¼¼´ë ÁßÀçÀû ½ÉÀ庴 Ä¡·á·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â °íµµÀÇ Àúħ½ÀÀûÀ̰í Á¤¹ÐÇÏ°Ô À¯µµµÈ ½Ã¼úÀ» ÅëÇØ ±¸Á¶Àû ½ÉÀåÁúȯ, °ü»óµ¿¸ÆÁúȯ, ÆÇ¸·ÁúȯÀ» Ä¡·áÇÏ´Â °ÍÀÔ´Ï´Ù. ±âÁ¸ÀÇ °³½É¼úÀº º¸´Ù ¾ÈÀüÇϰí ȯÀÚº°·Î ÃÖÀûÈ­µÈ Ä«Å×ÅÍ Ä¡·á·Î È®½ÇÈ÷ ÀüȯµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÇ·áÁøÀº ¾ÈÀü, Á¤È®¼º, ½Ã¼úÀÇ È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ ·Îº¿ °øÇÐ, AI ±â¹Ý À̹Ì¡, ÃÖ÷´Ü ÀÇ·á±â±â ±â¼úÀ» Á¡Á¡ ´õ ¸¹ÀÌ È°¿ëÇϰí ÀÖ½À´Ï´Ù. ÷´Ü Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë, Ä¡·á ºñ¿ë Àý°¨, ±Þ¼ÓÇÑ °í·ÉÈ­¿Í Àα¸ Áõ°¡¿¡ µû¸¥ ½ÉÇ÷°ü Áúȯ À¯º´·ü Áõ°¡¿¡ ´ëÇÑ ´ëÀÀ µî ÀÌ Áö¿ªÀÇ ÀÇ·á ¿ì¼±¼øÀ§´Â ÀÌ·¯ÇÑ ¹ßÀü°ú ¸ÆÀ» °°ÀÌ ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ÀÓ»ó °á°ú¸¦ °³¼±Çϰí ȸº¹ ½Ã°£À» ´ÜÃàÇÏ´Â È¿°úµµ °¡Á®¿Ô½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
¿¹Ãø ±â°£ 2025-2035³â
2025³â Æò°¡ 56¾ï 9,180¸¸ ´Þ·¯
2035³â ¿¹Ãø 130¾ï 5,370¸¸ ´Þ·¯
CAGR 8.46%

ÀÌ Áö¿ªÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀåÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Çѱ¹, Áß±¹, ÀϺ» µîÀÇ ±Þ¼ÓÇÑ °í·ÉÈ­¿Í ´õºÒ¾î Àεµ ¹× µ¿³²¾Æ½Ã¾ÆÀÇ »ýȰ½À°üÀ¸·Î ÀÎÇÑ ½ÉÀåÁúȯ À§Çè Áõ°¡·Î ÀÎÇØ ±âÁ¸ÀÇ °³½É¼úÀ» ´ëüÇϴ ÷´Ü Ä«Å×ÅÍ Ä¡·á°¡ Áö¿ªÀûÀ¸·Î ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ Áö¿ªÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå¿¡¼­´Â ·Îº¿°øÇÐ, AI °­È­ ¿µ»ó, ÷´Ü ±â±â ±â¼úÀ» Ȱ¿ëÇÏ¿© Á¤È®µµ Çâ»ó, ÇÕº´Áõ °¨¼Ò, ºü¸¥ ȸº¹À» ½ÇÇöÇϰí ÀÖ½À´Ï´Ù. Áö¿ª ÀÇ·á ½Ã½ºÅÛ¿¡¼­´Â ¾à¹° ¿ëÃâ ½ºÅÙÆ®, »ýü Èí¼ö¼º ½ºÄ³Æúµå, °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR), °æÇÇÀû ½Â¸ðÆÇ¸· ġȯ¼ú(TMVR) µîÀÇ ±â¼úÀÌ µµÀԵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ÇÏÀ̺긮µå Ä«Å×ÅÍ °Ë»ç½Ç, µðÁöÅÐ Çコ ÅëÇÕÀÇ È®´ë·Î ȯÀÚÀÇ Ã·´Ü Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

°¢±¹ Á¤ºÎ´Â ÀÚ±Ý Áö¿ø ÇÁ·Î±×·¥, À¯¸®ÇÑ »óȯ Á¦µµ, ÀÎÇÁ¶ó ÅõÀÚ¸¦ ÅëÇØ ÀÇ·á Çö´ëÈ­¸¦ Àû±ØÀûÀ¸·Î ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ Áß±¹°ú Àεµ¿¡¼­´Â ÇöÀç ´ë±Ô¸ð º´¿ø È®ÀåÀÌ ÁøÇà ÁßÀÔ´Ï´Ù. ÀÇ·á Á¢±Ù¼º °ÝÂ÷, ºñ¿ë ºÎ´ã µîÀÇ °úÁ¦°¡ ³²¾ÆÀÖÁö¸¸, Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß ³ë·Â, ¼¼°è ÀÇ·á±â±â ±â¾÷°ú Áö¿ª ±â¾÷ °£ÀÇ ÆÄÆ®³Ê½Ê, ȯÀÚ ÀÎ½Ä °³¼± µîÀÌ ÀÌ Áö¿ªÀ» Â÷¼¼´ë ÁßÀçÀû ½ÉÀ庴 Ä¡·áÀÇ ±Þ¼ºÀå ½ÃÀåÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼ºÐÈ­ 1: Á¦Ç° À¯Çüº°

  • ·Îº¸Æ½½º
    • ·Îº¿ º¸Á¶ °æÇÇÀû °ü»óµ¿¸Æ ÁßÀç¼ú(R-PCI)
    • ·Îº¿ º¸Á¶ °ü»óµ¿¸Æ ¿ìȸ¼ú(RA-CABG)
    • ·Îº¿ º¸Á¶ ½Â¸ðÆÇ¸· ġȯ¼ú(RMVR)
    • ·Îº¿ º¸Á¶ ´ëµ¿¸Æ ÆÇ¸· ġȯ¼ú
  • ºñ·Îº¸Æ½½º
    • IVUS
    • OCT
    • ±âŸ
      • ½ºÅÙÆ®
      • Ä«Å×ÅÍ
      • °¡À̵å¿ÍÀ̾î
      • PTCA dz¼±
      • ±âŸ

¼¼ºÐÈ­ 2 : ÀûÀÀÁõ À¯Çüº°

  • ±¸Á¶Àû ½ÉÀå Áúȯ
  • °ü»óµ¿¸Æ Áúȯ
  • ½ÉÀå ÆÇ¸·Áõ
  • ¸»Ãʵ¿¸Æ Áúȯ
  • ¼±Ãµ¼º ½ÉÀå Áúȯ

¼¼ºÐÈ­ 3: ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø ¹× Ŭ¸®´Ð
  • ½ÉÀå¼¾ÅÍ
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ

¼¼ºÐÈ­ 4: Áö¿ªº° ¼¼ºÐÈ­

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Àεµ
    • Áß±¹
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Â÷¼¼´ë ÀÎÅͺ¥¼Ç ½ÉÀåÁúȯ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ÁÖ¿ä µ¿Çâ, ½ÃÀå ¿µÇâ¿äÀÎ ºÐ¼®, ¹ý ¹× ±ÔÁ¦ ȯ°æ, ±â¼ú-ÆÄÀÌÇÁ¶óÀÎ µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢Á¾ ºÎ¹®º°/Áö¿ªº°/ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

¹üÀ§¿Í Á¤ÀÇ

Á¦1Àå Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå : ¾÷°è Àü¸Á

  • °æÀï ±¸µµ
    • »ç¾÷ Àü·«
  • Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå : Áø´Ü°ú °ü¸®
  • °ü»óµ¿¸Æ ÀÎÅͺ¥¼Ç Áøº¸
  • °ü»óµ¿¸Æ ÀÎÅͺ¥¼ÇÀÇ ÇâÈÄ ¹æÇ⼺°ú ½Å±â¼ú
  • Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • ±ÔÁ¦ »óȲ
    • ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦2Àå ½ÃÀå ¿ªÇÐ

  • µ¿Çâ
    • Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå µ¿Çâ
  • ½ÃÀå ¿ªÇÐ
    • µ¿Çâ, ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ : ÇöÀç ¹× ÇâÈÄ ¿µÇâ Æò°¡
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦

Á¦3Àå Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå : Áö¿ªº°

  • Áö¿ª ¿ä¾à
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áö¿ª °³¿ä
    • ½ÃÀå ¼ºÀå ¿øµ¿·Â
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ

Á¦4Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

  • ±â¾÷ °³¿ä
    • Terumo Corporation

Á¦5Àå Á¶»ç ¹æ¹ý

LSH 25.09.05

This report can be delivered in 2 working days.

Introduction to Asia-Pacific Next-Generation Intervention Cardiology Market

The Asia-Pacific next-generation intervention cardiology market is projected to reach $13,053.7 million by 2035 from $5,340.9 million in 2024, growing at a CAGR of 8.46% during the forecast period 2025-2035. Asian-Pacific (APAC) cardiac care is being revolutionized by next-generation interventional cardiology, which uses advanced, minimally invasive, precision-guided procedures to treat structural heart defects, coronary artery disease, and valvular illnesses. Traditional open-heart surgeries are clearly giving way to safer, more patient-specific catheter-based procedures around the region. In order to improve safety, accuracy, and procedural efficiency, healthcare professionals in Asia-Pacific are increasingly utilizing robotics, AI-driven imaging, and cutting-edge gadget technologies. The region's healthcare priorities of increasing access to cutting-edge therapies, lowering treatment costs, and addressing the rising prevalence of cardiovascular diseases in rapidly aging and growing populations are all in line with this advancement, which also improves clinical outcomes and speeds up recovery times.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$5,691.8 Million
2035 Forecast$13,053.7 Million
CAGR8.46%

Market Introduction

The market for next-generation interventional cardiology in Asia-Pacific (APAC) is expanding significantly due to the rising prevalence of cardiovascular illnesses and the growing need for minimally invasive procedures. Advanced catheter-based procedures are becoming more popular in the region as alternatives to traditional open-heart surgeries because to the rapidly aging populations in nations like South Korea, China, and Japan as well as the rising lifestyle-related cardiac risks in India and Southeast Asia.

Robotics, AI-enhanced imaging, and cutting-edge device technologies are all used in APAC's next-generation interventional cardiology to provide increased precision, fewer problems, and quicker recovery. The region's healthcare systems are increasingly implementing technologies including drug-eluting stents, bioresorbable scaffolds, transcatheter aortic valve replacement (TAVR), and transcatheter mitral valve repair (TMVR). Furthermore, patient access to these cutting-edge treatments is being increased by the rise of ambulatory surgery centers, hybrid cath laboratories, and digital health integration.

With funding programs, advantageous reimbursement practices, and infrastructure expenditures, governments throughout Asia-Pacific are aggressively promoting healthcare modernization. This is especially true in China and India, where massive hospital expansions are currently taking place. While challenges such as disparities in healthcare access and cost pressures persist, continuous R&D efforts, partnerships between global medtech firms and local players, and increasing patient awareness are positioning APAC as a fast-emerging market for next-generation interventional cardiology.

Market Segmentation:

Segmentation 1: By Product Type

  • Robotics
    • Robotic-Assisted Percutaneous Coronary Intervention (R-PCI)
    • Robotic-Assisted Coronary Artery Bypass Grafting (RA-CABG)
    • Robotic Assisted Mitral Valve-Replacement (RMVR)
    • Robotic Assisted Aortic Valve Replacement
  • Non-Robotics
    • IVUS
    • OCT
    • Other Interventions
      • Stents
      • Catheters
      • Guidewires
      • PTCA Balloons
      • Others

Segmentation 2: By Indication Type

  • Structural Heart Disease
  • Coronary Heart Diseases
  • Valvular Heart Diseases
  • Peripheral Artery Diseases
  • Congenital Heart Diseases

Segmentation 3: By End User

  • Hospitals and Clinics
  • Cardiac Centers
  • Ambulatory Surgical Centers

Segmentation 4: By Region

  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific

APAC Next-Generation Intervention Cardiology Market Trends, Drivers and Challenges

Trends

  • Rapid shift from open-heart surgery to minimally invasive catheter-based procedures.
  • Growing adoption of robotics, AI-enhanced imaging, and 3D navigation in interventional cardiology.
  • Rising uptake of TAVR (Transcatheter Aortic Valve Replacement), TMVR (Transcatheter Mitral Valve Repair), bioresorbable scaffolds, and drug-coated balloons.
  • Expansion of hybrid cath labs and ambulatory surgical centers across urban and semi-urban regions.
  • Integration of digital health, telecardiology, and remote monitoring into cardiovascular care.
  • Increasing cross-border collaborations between global medtech firms and regional healthcare providers.

Drivers

  • High prevalence of cardiovascular diseases due to aging populations and lifestyle factors (e.g., diabetes, obesity, hypertension).
  • Rising healthcare investments in China, India, Japan, and South Korea to expand advanced cardiology services.
  • Strong push for healthcare modernization through government-funded programs and infrastructure expansion.
  • Growing patient awareness and demand for safer, faster, and less invasive treatment options.
  • Increasing medical tourism in APAC (particularly India, Thailand, and Singapore) for advanced cardiac procedures.

Challenges

  • Healthcare access disparities between urban and rural areas across APAC.
  • High procedure and device costs limiting widespread adoption in developing economies.
  • Complex regulatory environments and approval delays for next-gen medical devices.
  • Shortage of skilled interventional cardiologists and trained staff in emerging markets.
  • Reimbursement gaps and limited insurance coverage for advanced procedures in several countries.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in APAC next-generation intervention cardiology, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses in APAC next-generation intervention cardiology and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines specific to APAC next-generation intervention cardiology, ensuring organizations stay compliant and accelerate market entry for new next-generation intervention cardiology

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Table of Contents

Executive Summary

Scope and Definition

1 Next-Generation Intervention Cardiology Market: Industry Outlook

  • 1.1 Competitive Landscape
    • 1.1.1 Business Strategies
      • 1.1.1.1 Product Developments in Next-Generation Intervention Cardiology Market
  • 1.2 Next-Generation Intervention Cardiology Market: Diagnosis and Management
  • 1.3 Advancements in Coronary Intervention
  • 1.4 Future Direction and Emerging Technologies in Coronary Interventions
  • 1.5 Pipeline Products in the Next-Generation Intervention Cardiology Market
  • 1.6 Regulatory Landscape
    • 1.6.1 Asia-Pacific
      • 1.6.1.1 Japan
      • 1.6.1.2 China
      • 1.6.1.3 India

2 Market Dynamics

  • 2.1 Trends
    • 2.1.1 Trends in the Next-Generation Intervention Cardiology Market
      • 2.1.1.1 Shift towards Minimally Invasive and Percutaneous Procedures Transforming Treatment Paradigms
      • 2.1.1.2 Integration of AI-Predictive Intelligence in Intervention Cardiology
        • 2.1.1.2.1 AI in Imaging, Lesion Assessment, and Diagnostics
  • 2.2 Market Dynamics
    • 2.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 2.2.2 Market Drivers
      • 2.2.2.1 Rising Elderly Population, Driving Demand for Advanced Cardiac Interventions
        • 2.2.2.1.1 Cardiovascular Disease Burden in the Elderly
      • 2.2.2.2 Emergence of Robotic-Assisted Interventions- Enhancing Procedural Accuracy and Operator Control
    • 2.2.3 Market Restraints
      • 2.2.3.1 High Procedural Cost and Infrastructure Burden Limiting Broad Adoption
      • 2.2.3.2 Regulatory Complexity and Prolonged Approval Timelines Hindering Innovation
        • 2.2.3.2.1 Lengthy Approval Pathways for High-Risk Devices
        • 2.2.3.2.2 Lack of Harmonization across Geographies
        • 2.2.3.2.3 Regulatory Gaps for AI and Software-Driven Devices
    • 2.2.4 Market Opportunities
      • 2.2.4.1 Stent and Balloon Innovation Unlocking Next-Generation Use Cases
        • 2.2.4.1.1 Advancements in Drug-Coated Balloon Technologies
      • 2.2.4.2 Remote and Robotic-Enabled Expansion into Emerging Markets
        • 2.2.4.2.1 Bridging Access Gaps through Remote Robotics
    • 2.2.5 Market Challenges
      • 2.2.5.1 Data Standardization and Clinical Validation Gaps in AI-Driven Cardiology
      • 2.2.5.2 Safety and Clinical Validation Barriers for Next-Generation Vascular Implants

3 Next-Generation Intervention Cardiology Market (Region), Value ($million), 2024-2035

  • 3.1 Regional Summary
  • 3.2 Asia-Pacific
    • 3.2.1 Regional Overview
    • 3.2.2 Driving Factors for Market Growth
    • 3.2.3 Factors Challenging the Market
    • 3.2.4 Japan
    • 3.2.5 China
    • 3.2.6 India
    • 3.2.7 Australia
    • 3.2.8 South Korea
    • 3.2.9 Rest-of-Asia-Pacific

4 Competitive Landscape and Company Profiles

  • 4.1 Company Profiles
    • 4.1.1 Terumo Corporation
      • 4.1.1.1 Overview
      • 4.1.1.2 Top Products/Product Portfolio
      • 4.1.1.3 Top Competitors
      • 4.1.1.4 Target Customers
      • 4.1.1.5 Strategic Positioning and Market Impact
      • 4.1.1.6 Analyst View
      • 4.1.1.7 Pipeline and Research Initiatives

5 Research Methodology

  • 5.1 Data Sources
    • 5.1.1 Primary Data Sources
    • 5.1.2 Secondary Data Sources
    • 5.1.3 Inclusion and Exclusion
    • 5.1.4 Data Triangulation
  • 5.2 Market Estimation and Forecast
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦